We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BridgeBio Pharma (BBIO) Down 10.7% Since Last Earnings Report: Can It Rebound?
Read MoreHide Full Article
A month has gone by since the last earnings report for BridgeBio Pharma (BBIO - Free Report) . Shares have lost about 10.7% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is BridgeBio Pharma due for a breakout? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for BridgeBio Pharma, Inc. before we dive into how investors and analysts have reacted as of late.
Q2 Earnings Miss, Sales Beat Estimates
BridgeBio reported a second-quarter 2026 loss of 78 cents per share, wider than the Zacks Consensus Estimate of a loss of 64 cents. Despite the miss, the figure improved compared to the year-ago loss of 95 cents.
Revenues surged 120% year over year to $243.7 million, beating the Zacks Consensus Estimate of $222.6 million. This growth was primarily driven by Attruby.
Attruby Sales Drive the Top Line
Attruby generated $222.4 million from product sales in the United States. The figure more than tripled from the $71.5 million recorded in the year-ago period.
Per BridgeBio, Attruby continued to gain share among treatment-naive patients, which management views as the key long-term growth driver for the franchise. Meanwhile, the pool of patients switching from Pfizer’s Vyndaqel/Vyndamax, a key competing ATTR-CM therapy, has begun to normalize after elevated switching activity in prior quarters. Management expects continued first-line share gains to support sales growth going forward.
Royalty revenues increased to $15.4 million from $1.6 million, primarily reflecting Attruby sales in the EU and Japan, where it is marketed as Beyonttra.
License and services revenues fell more than 84% year over year to $5.8 million, as the prior-year period benefited from a $30 million regulatory milestone.
Costs Rise on Commercial Investments
Research and development expenses increased 34% year over year to $149.4 million, reflecting continued investment in late-stage programs.
Selling, general and administrative expenses climbed 44% to $186.3 million as the company supported Attruby commercialization and pre-commercial work for upcoming launches.
As of June 30, 2026, cash, cash equivalents and marketable securities totaled $720.2 million, down from $940.2 million in the previous quarter. The figure excludes the $1 billion preferred equity financing that closed July 1, which lifted the company's cash balance to about $1.7 billion.
How Have Estimates Been Moving Since Then?
Since the earnings release, investors have witnessed a downward trend in estimates review.
The consensus estimate has shifted -18.21% due to these changes.
VGM Scores
At this time, BridgeBio Pharma has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. Following the exact same course, the stock has a score of F on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, BridgeBio Pharma has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
BridgeBio Pharma belongs to the Zacks Medical - Generic Drugs industry. Another stock from the same industry, Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) , has gained 0.8% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026.
Teva Pharmaceutical Industries reported revenues of $4.14 billion in the last reported quarter, representing a year-over-year change of -0.8%. EPS of $0.02 for the same period compares with $0.66 a year ago.
For the current quarter, Teva Pharmaceutical Industries is expected to post earnings of $0.71 per share, indicating a change of -9% from the year-ago quarter. The Zacks Consensus Estimate has changed -2.8% over the last 30 days.
Teva Pharmaceutical Industries has a Zacks Rank #4 (Sell) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C.
View the Zacks #1 Rank List
Image: Bigstock
BridgeBio Pharma (BBIO) Down 10.7% Since Last Earnings Report: Can It Rebound?
A month has gone by since the last earnings report for BridgeBio Pharma (BBIO - Free Report) . Shares have lost about 10.7% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is BridgeBio Pharma due for a breakout? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for BridgeBio Pharma, Inc. before we dive into how investors and analysts have reacted as of late.
Q2 Earnings Miss, Sales Beat Estimates
BridgeBio reported a second-quarter 2026 loss of 78 cents per share, wider than the Zacks Consensus Estimate of a loss of 64 cents. Despite the miss, the figure improved compared to the year-ago loss of 95 cents.
Revenues surged 120% year over year to $243.7 million, beating the Zacks Consensus Estimate of $222.6 million. This growth was primarily driven by Attruby.
Attruby Sales Drive the Top Line
Attruby generated $222.4 million from product sales in the United States. The figure more than tripled from the $71.5 million recorded in the year-ago period.
Per BridgeBio, Attruby continued to gain share among treatment-naive patients, which management views as the key long-term growth driver for the franchise. Meanwhile, the pool of patients switching from Pfizer’s Vyndaqel/Vyndamax, a key competing ATTR-CM therapy, has begun to normalize after elevated switching activity in prior quarters. Management expects continued first-line share gains to support sales growth going forward.
Royalty revenues increased to $15.4 million from $1.6 million, primarily reflecting Attruby sales in the EU and Japan, where it is marketed as Beyonttra.
License and services revenues fell more than 84% year over year to $5.8 million, as the prior-year period benefited from a $30 million regulatory milestone.
Costs Rise on Commercial Investments
Research and development expenses increased 34% year over year to $149.4 million, reflecting continued investment in late-stage programs.
Selling, general and administrative expenses climbed 44% to $186.3 million as the company supported Attruby commercialization and pre-commercial work for upcoming launches.
As of June 30, 2026, cash, cash equivalents and marketable securities totaled $720.2 million, down from $940.2 million in the previous quarter. The figure excludes the $1 billion preferred equity financing that closed July 1, which lifted the company's cash balance to about $1.7 billion.
How Have Estimates Been Moving Since Then?
Since the earnings release, investors have witnessed a downward trend in estimates review.
The consensus estimate has shifted -18.21% due to these changes.
VGM Scores
At this time, BridgeBio Pharma has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. Following the exact same course, the stock has a score of F on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, BridgeBio Pharma has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
BridgeBio Pharma belongs to the Zacks Medical - Generic Drugs industry. Another stock from the same industry, Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) , has gained 0.8% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026.
Teva Pharmaceutical Industries reported revenues of $4.14 billion in the last reported quarter, representing a year-over-year change of -0.8%. EPS of $0.02 for the same period compares with $0.66 a year ago.
For the current quarter, Teva Pharmaceutical Industries is expected to post earnings of $0.71 per share, indicating a change of -9% from the year-ago quarter. The Zacks Consensus Estimate has changed -2.8% over the last 30 days.
Teva Pharmaceutical Industries has a Zacks Rank #4 (Sell) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C.